Stock Detail
Videos
Reviva Pharmaceuticals (RVPH) Fireside Chat
During this fireside chat webcast, we welcome Reviva Pharmaceuticals, ticker symbol RVPH on the NASDAQ. Joining us today from the company is Lax Bhat, Reviva's Chief Executive Officer. Also joining us is Jim Molloy, Senior Research Analyst with Alliance Global...
Reviva Pharmaceuticals (RVPH) Fireside Chat
During this fireside chat, we welcome Reviva Pharmaceuticals, ticker, RVPH on the NASDAQ, and their CEO, Dr. Lax Bhat. Reviva is a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system...
Phase 3 Drugs to Watch KOL Panel
This panel presentation features executives from three different companies that are looking to advance innovations in healthcare, each of them with ongoing or planned Phase 3 trials here. We've titled the panel, Phase 3 Drugs to Watch. Hosted by Lytham Partners...
News
Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
CUPERTINO, Calif., Oct. 02, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference
CUPERTINO, Calif., Sept. 26, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
- Statistically significant vocal biomarker speech latency data reinforce the strong efficacy of brilaroxazine for negative symptoms and other key symptom domains of schizophrenia - - Additional vocal biomarker data from ongoing open label extension study evaluating...